“Targets for Tomorrow” Workshop at GRC in Italy July 2013

We invite you to join us for the “Targets for Tomorrow” satellite workshop hosted by the WGND Biology/Targets Subgroup on Monday, July 22, 2013 from 2 p.m. to 4:30 p.m. at the Renaissance Tuscany Il Ciocco Resort, Lucca (Barga), Italy. The workshop is held in conjunction with the Gordon Conference on TB Drug Development (July 21-26). The objectives of the meeting are to:

  • Allow key entities involved strategically in TB drug discovery to present their views of the needs, directions and targets for tomorrow to the research community
  • Discuss the puzzling finding of ‘promiscuous targets’
  • Set a priority list of what constitutes good targets and what does not to develop a universal “go/no go” checklist for targets
“Targets For Tomorrow” Satellite Workshop
Workshop Chair: Thomas Dick
2:00 p.m.-3:15pm: Needs & directions in TB drug discovery–Leader: Petros KarakousisSession Speakers:
  • Barbara Laughon (NIAID/NIH)
  • Ken Duncan (Bill & Melinda Gates Foundation)
  • Anna Upton (TB Alliance)
  • Alfonso Mendoza-Losana (GlaxoSmithKline)
  • Petros Karakousis (Johns Hopkins)
3:15-3:30pm: Break
3:30-4:30pm: ‘Promiscuous targets’–Leader: Tanya ParishDiscussion Topics:
  • What makes a good target—Speaker: Bavesh Kana
  • Results from current target ID efforts– Speaker: Dirk Schnappinger
  • Are promiscuous targets good or bad– Speaker: TBD
  • Best approaches to target-based screening—Speaker: Helena Boshoff

Light refreshments will be served.

If you plan on attending the satellite workshop, please RSVP by e-mailing

More News
17 Sep 2019
Earlier this month, the NIH announced two new Funding Opportunity Annoucnements (FOAs) on the topic of Myeloid-Derived Suppressor Cells (MDSC) as potential therapeutic targets in TB/HIV co-infected patients. The purpose of these FOAs is to invite applications for support of innovative clinical,...
14 Aug 2019
FDA released the following press release on Wednesday, August 14th: The U.S. Food and Drug Administration today approved Pretomanid Tablets in combination with bedaquiline and linezolid for the treatment of a specific type of highly treatment-resistant tuberculosis (TB) of the lungs. “The threat of...
27 Jun 2019
-- Globe Newswire reported on June 20th -- Spero Therapeutics, Inc. , a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections and rare diseases, today...